WBA

WBA - Walgreen Boots Alliance Ord Shs

SPECULATIVE BUYREDUCE ZONEHealthcare - Medical - Pharmaceuticals2026-08-09Data 34 days oldMXN 222.00

Conviction

out of 100

Executive Summary

Walgreen Boots Alliance Ord Shs (WBA) is a pharmacy-led retail and healthcare group that operates the largest drugstore chain in the United States by store count, alongside a UK pharmacy and beauty business (Boots) and a European pharmaceutical wholesale and distribution business (Alliance Healthcare). Its core proposition is dispensing prescription medicines, particularly under Medicare Part D, supplemented by front-of-store health and beauty merchandise and a growing portfolio of primary care and health-services assets.

The investment case rests almost entirely on a confirmed take-private of the company by Sycamore Partners, in partnership with Stefano Pessina and his family, which has already closed. The relevant near-term question is the price at which any residual or unconfirmed consideration flows to shareholders and whether the delisting mechanics produce an arbitrage opportunity. The primary risk is that the take-private has completed, the common stock has ceased trading on Nasdaq and the residual Mexican Bolsa listing tracks an illiquid, sparsely traded line that may not deliver the implied deal economics to late-stage buyers.

SPECULATIVE BUY. Conviction Score: 49/100. The view would be upgraded on confirmation that residual share entitlements match the take-private consideration without further dilution, and downgraded if the Mexican Bolsa quotation decouples from the underlying deal economics or if trading liquidity evaporates further.

Trim / take some off. Current price MXN 222.00 is 8.3% above the trim line of MXN 205.00. Existing holders should reduce; new money should wait.

REDUCE ZONESPECULATIVE BUY · 49/100Now MXN 222.00 · buy ≤ MXN 168.33 · trim ≥ MXN 205.00

Thesis break: The Sycamore Partners take-private is reversed or unwound, residual BMV shareholders are definitively excluded from the deal consideration, or the Mexican Bolsa quotation is formally suspended.

Business Model

WBA generates revenue principally through three segments. In the United States Retail Pharmacy, the group fills prescriptions across approximately 8,500 Walgreens stores, sells front-of-store consumer goods and runs adjacent health services; this segment also includes the primary care clinic investment in Village Medical and legacy health-tech assets. In the UK, the Boots business operates a pharmacy and beauty chain with a strong own-label portfolio that has historically outperformed the US operation. Internationally, Alliance Healthcare distributes pharmaceuticals to independent pharmacies and hospitals across Europe, providing a wholesale margin stream that is more stable than retail.

The traditional competitive moat has been scale: the largest US retail pharmacy footprint, an in-store health-and-beauty cross-sell, and buying power with pharmaceutical manufacturers and Pharmacy Benefit Managers (PBMs). That moat has narrowed as PBM consolidation has shifted margin to the payer side, as mail-order and online pharmacies have absorbed script volume, and as footfall in physical retail has structurally declined. The company has responded with cost actions including the closure of roughly 1,200 US stores (around 12% of the US fleet), dividend cuts to preserve capital, and exit from non-core assets such as the Shields Health joint venture.

Customer mix is dominated by third-party payers in the prescription book (Medicare Part D, Medicaid managed care and commercial plans), with cash-paying customers more material in front-of-store and in the UK Boots business. Earnings power has been impaired by large goodwill write-downs against Boots and Village Medical, and reported margins have been compressed by reimbursement pressure from consolidated PBMs and by US store-level deleverage as closures were implemented.

Financial Snapshot

Price

MXN 222.00

Market Cap

MXN 10.4bn

52w High

MXN 269.00

52w Low

MXN 161.00

Distance from 52wH

-17.5%

Avg Volume

442

Currency

MXN

Recent Catalysts

[27 August 2025] - Sycamore Partners completed the acquisition of Walgreens Boots Alliance in partnership with Stefano Pessina and his family, through Blazing Star Merger Sub, Inc.; WBA common stock ceased trading and was delisted from Nasdaq. Source: Business Wire press release.

[27 August 2025] - Blazing Star Merger Sub, Inc. announced the final results of the tender offer connected to the Sycamore Partners buyout of Walgreens Boots Alliance. Source: StockTitan news bulletin.

[2025 financial year] - Walgreens Boots Alliance reported materially collapsed earnings, with large impairments against the Boots and Village Medical goodwill balances and multiple consecutive quarterly earnings misses; the company cut its dividend to preserve capital. Source: StockTitan WBA overview page.

[2025 - 2026] - Management continued execution of the US store-closure programme, totalling roughly 1,200 stores (around 12% of the US fleet), and exited the Shields Health Solutions PBM-adjacent joint venture as part of a broader portfolio simplification. Source: StockTitan WBA overview page.

Thesis Evaluation

Bull Case (16% weight)

The take-private consideration flows through to residual Mexican Bolsa listings at or near the implied per-share value, and any rump shareholders receive a clean cash payout with no further dilution from transaction expenses or post-close adjustments. Liquidity remains sufficient for tactical positioning. Price target MXN260 within 6 months.

Base Case (48% weight)

The residual BMV quotation tracks broadly in line with the underlying deal economics but at a discount of 10 - 15% to reflect illiquidity and execution risk; reported earnings remain weak and no operational recovery is visible. Price target MXN205 over 12 months, with most of the return coming from any convergence to deal value rather than operating improvement.

Bear Case (36% weight)

The BMV line decouples from the closed take-private transaction, trading becomes effectively uninvestable, and the underlying business deteriorates further under private ownership with no public disclosure mechanism, leaving residual holders with a stale quotation below the deal reference. Price target MXN150 within 12 months.

Weighted conviction:Bull (16%) x 100 + Base (48%) x 62 + Bear (36%) x 10 = 49/100. SPECULATIVE BUY.

Key Risks

Take-private decoupling risk: The residual Mexican Bolsa quotation for WBA may trade persistently below the implied Sycamore deal value because the underlying transaction is closed and there is no live tender mechanism for rump holders. Estimated probability: 40%. Impact: severe.
Liquidity and trading continuity risk: With the Nasdaq listing cancelled, BMV trading volume may collapse, leading to wide bid-ask spreads and an inability to exit positions at quoted prices. Estimated probability: 55%. Impact: severe.
Pharmacy margin compression: PBM consolidation continues to shift reimbursement terms against retail pharmacies, compressing US script margins even under private ownership. Estimated probability: 70%. Impact: severe.
Goodwill and asset impairment risk: Further write-downs against Boots, Village Medical or other legacy assets cannot be ruled out given the multi-year earnings decline. Estimated probability: 35%. Impact: moderate.
Structural US foot-traffic decline: Continued migration of prescriptions to mail-order and online channels reduces store-level volumes and undermines the remaining US retail estate. Estimated probability: 65%. Impact: moderate.
Regulatory and reporting risk: Reduced public-company disclosure post-delisting limits transparency on financial performance and increases information asymmetry for residual public holders. Estimated probability: 80%. Impact: low.

Who Should Own It / Avoid It

Ideal for: experienced, risk-tolerant investors with a minimum holding period of 6 - 12 months who understand merger-arb and post-delisting residual dynamics, are comfortable with illiquid Mexican Bolsa trading, and are sizing positions small enough that a permanent loss of 30 - 40% of capital is absorbable. Speculative positioning is appropriate only for investors who have an explicit thesis on how residual shares reconcile to the closed Sycamore consideration.

Avoid if: you require liquid US exchange trading, need regular audited public reporting, are a long-only institutional mandate constrained to index-eligible Nasdaq securities, or cannot tolerate the possibility that the BMV line decouples from the underlying transaction and trades as a stub indefinitely.

Recommendation

SPECULATIVE BUY - 49/100. The call reflects a narrowly positive asymmetry: the take-private is closed and confirmed, but the residual BMV quotation currently sits well below the 52-week high and offers optionality on convergence to deal value, while the operational picture is clearly negative with collapsed earnings, impairments and structural pharmacy margin pressure. The view would be upgraded on clear confirmation that residual BMV shareholders will receive the full Sycamore consideration without further discount, or on evidence that the quotation is converging towards the deal-implied price. It would be degraded if the BMV line decouples from the underlying transaction, if trading liquidity collapses to the point of effective uninvestability, or if any further material impairment or covenant issue is disclosed post-delisting. At the current price of MXN222.00 the shares trade at or above our base-case target of MXN205.00: the base case is fully priced, existing holders should consider trimming, and new positions are not advised above MXN168.33.

The probability-weighted value across our three scenarios is MXN194.00, 13% below the current price of MXN222.00 - the market is currently pricing the shares ahead of our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.

BUY

below MXN168.33 - below this level the upside to the base-case target (MXN205.00) is at least 2x the downside to the bear case (MXN150.00), the minimum risk/reward we require before committing new capital.

HOLD

between MXN168.33 and MXN205.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.

REDUCE

above MXN205.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 16%.

SELL

if the Sycamore Partners take-private is reversed or unwound, residual BMV shareholders are definitively excluded from the deal consideration, or the Mexican Bolsa quotation is formally suspended, regardless of price - the bear target of MXN150.00 is the backstop, not an arbitrary percentage stop.

Conviction Trend

Latest conviction: 49/100. Trend versus prior report: Flat.

CONVICTION BUY (80+)BUY (65 - 79)OPP BUY (50 - 64)SPEC BUY (30 - 49)AVOID (0 - 29)

Report date	Conviction
2026-08-09	49
2026-07-25	49
2026-06-28	54
2026-05-30	40
2026-04-28	40

See the trade-card view →

Sources

Market data: DYOR HQ proprietary market data workflow.

Public sentiment and news flow: Public news flow was used, including the Business Wire press release announcing the completion of the Sycamore Partners acquisition, StockTitan bulletins on the tender offer final results and WBA corporate updates, Yahoo Finance reporting on the Sycamore buyout close, Google Finance price and news coverage, and aggregator commentary on WBA's operational and post-delisting status.

Primary source types: Company press releases and investor relations materials, regulatory and exchange delisting notices, earnings announcements and earnings date schedules, and third-party financial news reporting on the Sycamore Partners transaction and subsequent corporate events.

Key sources

Data correct as of 2026-08-09